Disease Modification of Asthma by molecules derived from TB bacteria

结核病细菌(MTB)存在于全球约20亿人中；它们经过数千年的进化，通过产生调节宿主免疫系统的蛋白质而隐藏在体内。这些蛋白质已被证明与人体的自然炎症过程相互作用并减少。PeptInnoate的创新方法是解锁这些蛋白质的抗炎活性，并开发治疗哮喘和慢性阻塞性肺病等衰弱疾病的新药。在进化、自然的独创性和利用PeptInnoate的药物发现和开发技术的基础上，我们已经将这些蛋白质修饰为更多的类药物分子，并正在将第二分子PIN201104推向临床。目的遵循领先候选PIN201104的小鼠屋尘螨(HDM)哮喘模型中令人兴奋的临床前数据，PeptInnoate将使该分子进展到体内和体外作用机制研究；解开PIN201104在哮喘动物模型中的作用机制，并将这一机制转化为人体细胞的体外环境。这些研究将导致用于健康志愿者临床研究的体外生物标记物分析，并指导PIN201104在严重类固醇折返性哮喘中的表型定位。目的·在小鼠哮喘模型中进行体内研究，以确定PIN201104是否影响呼吸道高反应性(哮喘)·进行体内研究，以确定PIN201104治疗哮喘的适当剂量方案和给药途径的益处、结果和影响全球炎症疾病治疗市场是巨大的(&GT；700亿美元)，然而最近的安全恐慌被归因于一些关键药物。Pept Innovate潜在治疗方案的范式转变将对数百万患者的生活产生深远影响，减轻医疗保健提供者的负担，并帮助将其打造成一家可持续的英国生物技术公司

Tuberculosis bacteria (mTB) are present in about 2 billion people worldwide; they haveevolved over millennia to remain hidden in the body by producing proteins that modulate thehost's immune system. These proteins have been shown to interact with and reduce the body'snatural inflammatory processes.Peptinnovate’s innovationPeptinnovate’s approach is to unlock the anti-inflammatory activity of these proteins and todevelop new medicines for debilitating diseases such as asthma and COPD. Building onevolution, nature's ingenuity and employing Peptinnovate’s drug discovery and developmentskills we have modified these proteins to more drug-like molecules and are progressing thecandidate molecule, PIN201104, to the clinic.AimsFollowing exciting preclinical data in the murine house dust mite (HDM) asthma model forthe lead candidate PIN201104 Peptinnovate will progress the molecule into in vivo and invitro mechanism of action studies to; unravel the mechanism of action of the peptide inasthma animal models and translate this mechanism into an in vitro setting in human cells.These studies will then lead to an in vitro biomarker assay for use in clinical studies in healthyvolunteers and guide phenotypic positioning of PIN201104 in severe, steroid refractiveasthma.Objectives• To perform in vivo studies in murine asthma models to determine if PIN201104effects airway hyperreactivity (asthma)• To perform in vivo studies to ascertain the appropriate dosing regimen and route ofdelivery for PIN201104 for the treatment of asthmaBenefits, outcomes and impactsThe worldwide market for inflammatory disease treatment is substantial (>$70 billion),however recent safety scares have been attributed to a number of key drugs. Peptinnovate’sparadigm shift in potential treatment options will have a profound impact on the lives ofmillions of patients, reducing the burden on the healthcare providers and helping to build asustainable UK biotech company